gene therapy

Our opinion piece in Science Signaling was published. It discusses the results by Kataru et al., and how they relate to the continuing (re)search for a lymphedema drug after the discontinuation of the clinical trials with Lymfactin.

Some feared, that the patent decisions on the CRISPR technology this spring might lead to a monopolization of the technology. However, according to a last month's article in Nature Methods, it is not at all clear at this moment, whether CRISPR will hit a home run for the editing of the human genome.